I agree , I hope I'm wrong but all indications imo are reason for concern. Lack of communication, funding, acquisition closing, no revenue, no pps to meet listing, no explanation of outcome last Divi fiasco, no institutional interest, no analyst coverage, no professional website to show potential and attract interest , no MSO target date, plenty litigation, plenty debt, increased total outstanding shares GNBT, no Covid update on progress incl BARDA/CEPI , increasing candidates WHO list (total160), no clinical trial update regarding recruitment, no China update .......just to name a few - I can go on but you get the pic. One positive note , most PR's since 2018 have been positive and at least 1-2B valuation ..............
Reviewing last Q3 confirms current situation .......now we just need accountability to move forward and/or make adjustments !!!